Risk Factors for Pulmonary Embolism in Patients with Lung Cancer and Effects of Pulmonary Embolism on Prognosis

Conclusion: Lung cancer patients with PE had a shorter survival. PE should be considered in patients with adenocarcinoma histology, leukocytosis, elevated CRP, anemia, and nutritional disorders. Results: The PE group’s median age was 61 years (45-82 years), while the non-PE group’s median age was 61 years (35-83 years). Adenocarcinoma was the most common histological form in the PE population, with higher leukocyte and C-reactive protein (CRP) levels and lower hemoglobin levels. The PE group had a mean survival time of 20.1±1.6 months, while the non-PE group had a mean survival time of 36.5±2.9 months. The mean survival time was significantly longer in the non-PE group (p<0.001). Materials and Methods: The study’s data came from lung cancer patients who were followed up between January 2012 and May 2017. A total of 235 patients with a thoracic angiographic computed tomography scan and/or ventilation/perfusion scintigraphy were included in the study. 109 patients with PE and 126 patients without a PE diagnosis were reported. Demographic information, lung cancer types and stages, time between lung cancer and PE, and survival were all recorded. Background: Malignancy is an important risk factor for venous thromboembolism. Lung cancer is one of the frequently determined cancer associated with pulmonary embolism (PE). In our research, we compared lung cancer patients diagnosed with PE at the same period and lung cancer patients without PE. Besides, we investigated the risk factors that could predict PE in lung cancer patients, whether survival was different between patients who were diagnosed with PE incidentally and those who were diagnosed proactively.